CLN4 Disease (Kufs Disease): A Patient Guide
At a Glance
CLN4 disease, also called Kufs disease, is a rare adult-onset neurological disorder caused by a pathogenic DNAJC5 variant and inherited in an autosomal dominant pattern. There is no cure yet, so care focuses on seizures, myoclonus, safety, communication, and emotional well-being.
CLN4 disease, also known under the clinical umbrella of Kufs disease, is a rare and complex neurological condition that typically begins in adulthood. It belongs to a group of disorders called the neuronal ceroid lipofuscinoses (NCLs), which are sometimes collectively referred to as Batten disease. Unlike the childhood forms of these disorders, CLN4 is unique because it is autosomal dominant, meaning it can be passed directly from one generation to the next, and it is notable for generally preserving a patient’s vision [1][2].
At its core, CLN4 is caused by a pathogenic variant in the DNAJC5 gene, which disrupts the way brain cells process and recycle proteins. This biological “glitch” leads to the buildup of a fatty substance called ceroid within nerve cells, eventually interfering with how the brain sends and receives signals [3][4]. While every person’s experience is different, the disease usually follows one of two overlapping patterns: one primarily involving seizures and sudden muscle jerks (myoclonus), and another defined more by changes in personality, thinking, and physical coordination [5][6].
Because the symptoms of CLN4—such as balance issues or memory changes—can look like many other neurological conditions, the journey to a correct diagnosis is often long. However, confirming the diagnosis through specialized genetic testing is a vital turning point. While there is currently no cure to stop the underlying progression of the disease, there is a great deal that can be done to manage symptoms and maintain quality of life. Modern care focuses on carefully managing seizures, protecting physical safety, and providing early support for communication and emotional health [7][8].
Living with CLN4 requires a proactive and compassionate approach to care. By building a dedicated team of specialists and focusing on practical daily support, patients and their families can navigate the changes the disease brings. The goal of this guide is to provide the clear, evidence-based information you need to advocate for yourself or your loved one, ensuring that you have the tools to make informed decisions and focus on what matters most [9][10].
In this guide
6 chapters
Understanding Your CLN4 (Kufs Disease) Diagnosis
Learn how CLN4 (Kufs disease) is diagnosed with DNAJC5 genetic testing, how symptoms progress, and how seizure, movement, and family needs are managed over time.
How CLN4 Disease Works and Look-Alikes
Learn how CLN4 disease affects brain-cell waste processing, why ceroid builds up, and how doctors distinguish it from other similar neurological conditions.
Symptoms, Patterns, and Disease Progression
Learn how CLN4 disease symptoms progress, including seizures, myoclonus, cognitive changes, parkinsonism, MRI findings, and planning for future support.
Diagnostic Testing and Understanding Your Genetics
Learn how CLN4 genetic testing confirms a DNAJC5 variant, why WES may miss complex changes, and how genetic counseling supports family testing and planning.
Standard of Care Treatment and Management
Learn how CLN4 disease is managed without a cure, including seizure medicines, rescue plans, therapy, medication risks, and experimental research options.
Building Your Care Team and Daily Support
Learn how CLN4 care teams support swallowing, breathing, seizures, mobility, mood, safety, caregiver support, and long-term planning with specialist guidance.
Common questions in this guide
What is CLN4 disease, and is it the same as Kufs disease?
How is CLN4 disease inherited?
What symptoms can CLN4 disease cause?
How is CLN4 disease diagnosed?
Is there a cure for CLN4 disease?
How can someone living with CLN4 prepare for changes in daily care?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my genetic report, can you confirm if my diagnosis is the autosomal dominant CLN4 form specifically?
- 2.Which clinical pattern—Type A or Type B—best describes my symptoms right now, and how might that change?
- 3.What is our plan for managing my seizures and muscle jerks while avoiding high-risk medications?
- 4.Can you help us identify the 'red flags' that would mean we need to adjust my home care or safety plan?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (10)
- 1
Evidence for Cholinergic Dysfunction in Autosomal Dominant Kufs Disease.
Jarrett P, Easton A, Rockwood K, et al.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2018; (45(2)):150-157 doi:10.1017/cjn.2017.261.
PMID: 29506599 - 2
Adult-onset neuronal ceroid lipofuscinosis misdiagnosed as autoimmune encephalitis and normal-pressure hydrocephalus: A 10-year case report and case-based review.
Huang H, Liao Y, Yu Y, et al.
Medicine 2024; (103(43)):e40248 doi:10.1097/MD.0000000000040248.
PMID: 39470529 - 3
A cluster of palmitoylated cysteines are essential for aggregation of cysteine-string protein mutants that cause neuronal ceroid lipofuscinosis.
Diez-Ardanuy C, Greaves J, Munro KR, et al.
Scientific reports 2017; (7(1)):10 doi:10.1038/s41598-017-00036-8.
PMID: 28127059 - 4
Cysteine string protein (CSP) and its role in preventing neurodegeneration.
Burgoyne RD, Morgan A
Seminars in cell & developmental biology 2015; (40()):153-9.
PMID: 25800794 - 5
Autosomal dominant Kufs disease in a Georgian adult woman: A case report.
Papiashvili N, Gagua S, Gonjilashvili N, et al.
Epilepsy & behavior reports 2025; (32()):100805 doi:10.1016/j.ebr.2025.100805.
PMID: 40688378 - 6
Kufs disease due to mutation of CLN6: clinical, pathological and molecular genetic features.
Berkovic SF, Oliver KL, Canafoglia L, et al.
Brain : a journal of neurology 2019; (142(1)):59-69 doi:10.1093/brain/awy297.
PMID: 30561534 - 7
Management of CLN1 Disease: International Clinical Consensus.
Augustine EF, Adams HR, de Los Reyes E, et al.
Pediatric neurology 2021; (120()):38-51 doi:10.1016/j.pediatrneurol.2021.04.002.
PMID: 34000449 - 8
The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.
Orsini A, Valetto A, Bertini V, et al.
Seizure 2019; (71()):247-257 doi:10.1016/j.seizure.2019.08.012.
PMID: 31476531 - 9
Unraveling Neuronal Ceroid Lipofuscinosis: Insights From Two Pediatric Cases in Peripheral India.
Aman N, Panapil AG, Utage P
Journal of child neurology 2026; (41(1)):89-93 doi:10.1177/08830738251346920.
PMID: 40545665 - 10
Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis.
Geraets RD, Koh Sy, Hastings ML, et al.
Orphanet journal of rare diseases 2016; (11()):40 doi:10.1186/s13023-016-0414-2.
PMID: 27083890
This page is for informational purposes only and does not constitute medical advice. Your neurologist and genetics team can interpret your genetic results and tailor symptom management, safety planning, and support to your situation.
Get notified when new evidence is published on CLN4 disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.